drugset / Trial / NCT06241898
A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are: * to assess the safety and tolerability of BB-1709. * to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709
Timeline
- Start
- 2023-10-01
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BB-1709 | Unknown | — | Intravenous |